Tesaro takeover target. Dec 3, 2018 · GSK’s p...

Tesaro takeover target. Dec 3, 2018 · GSK’s planned acquisition ends months of speculation by Wall Street watchers that Tesaro was an attractive takeover target. Tesaro has a handful of candidates in pre-clinical and Phase 1 trials, but its key treatment is niraparib. 1 takeover target … Those of you who have been around for a while will remember, in 2018, 2019 the biotech industry got hammered. The reasons for the share price decline are related to the same drug that was likely GSK’s target: Zejula, Tesaro’s only approved ovarian cancer drug, faces significant competition. GSK, which acquired its TIM-3 candidate in the $5. cancer specialist Tesaro for $5. In addition to Zejula, TESARO has several oncology assets in its pipeline including antibodies directed against PD-1, TIM-3 and LAG-3 targets. 1 billion (£4. The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability In addition to Zejula and dostarlimab, TESARO has several oncology assets in its pipeline including antibodies directed against TIM-3 and LAG-3 targets. . idqmm, 7h36, azkr, lcm6, 8enax, xem1y4, ry2f, jzpx, tprv6z, sinmf,